In the original publication, the following text "Printed with permission from ©Mount Sinai Health System" had been missed to include from Figs. 1 to 4 captions. The correct figure legends are given below. Multiple signals and pathways involve in processes of HSC activation. Key fibrogenic and proliferative mediators contribute to fibrogenesis, include tissue growth factor-b (TGF-b1), platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), and connective tissue growth factor (CTGF). Hedgehog (Hh) ligand and its receptor smoothened homolog (SMO). G proteincoupled receptors including cannabinoid receptor 1/2 receptors (CB1, CB2), 5-hydroxytryptamine receptors (5HTs), proteinase-activated receptor 2 (PAR2), C-C chemokine receptors (CCRs), succinate dehydrogenase-G protein-coupled receptor 91 (GPR91), type 1 angiotensin II receptor (AT1R) can affect HSC activation. Innate immune signalling induced by Toll-like receptors (TLRs), lipopolysaccharide, and damage-associated molecular patterns (DAMPs) has been implicated in stellate cell activation. Cytokines and chemokines mediate crosstalk between hepatic stellate cells and others non-parenchymal liver cells such as kupffer cell are also critical features in liver fibrogenesis. Endoplasmic reticulum (ER) stress and oxidative stress are features of chronic liver disease that activates HSCs. Alteration of nuclear receptors expression also involves in stellate cell activation both in positive and negative ways. Epigenetic signals including microRNAs (mi RNAs), DNA methylation and histone modification control both activation and inactivation of HSCs. FXR, farnesoid X receptor; LXR, liver X receptor; NR4A1, nuclear receptor subfamily 4 group A member 1; PPARs, peroxisome proliferator-activated receptors; VDR, vitamin D3 receptor; Rev-erb, nuclear receptor subfamily 1, group D, member 1. Printed with permission from ©Mount Sinai Health System  Fig. 4 Mechanisms by which antifibrotic therapies may lead to fibrosis regression.
[1] Reduction of HSC activation by reducing hepatic inflammatory response including removed injurious stimuli, introduced antioxidant, introduced hepatic protection agents and applied immune modulation.
[2] Inhibition of the most potent of the profibrogenic pathways, for example, preventing expression of The original article can be found online at https ://doi.org/10.1007/ s1207 2-018-9897-3. 
